Specifically, IL-25 has been shown to preferentially affect ILC2s and myeloid-derived suppressor cells (MDSCs) in CRC (81), while IL-33 exerts a more dominant effect on Th2 cells, Tregs, and mast cells (84, 87, 88, 91, 92, 94–96), although both can modulate eosinophils (82, 97). This evidence concerns the gene IL25 and colorectal carcinoma.